Trial record 33 of 75 for:
stem cell multiple sclerosis
Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03822858 |
|
Expanded Access Status :
Available
First Posted : January 30, 2019
Last Update Posted : September 10, 2019
|
Sponsor:
Tisch Multiple Sclerosis Research Center of New York
Information provided by (Responsible Party):
Tisch Multiple Sclerosis Research Center of New York
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Brief Summary:
To give expanded access to intrathecal autologous MSC-NP treatment to patients with progressive MS who do not meet the inclusion/exclusion criteria of our Phase II stem cell trial.
| Condition or disease | Intervention/treatment |
|---|---|
| Multiple Sclerosis | Drug: Intrathecal MSC-NP injection |
| Study Type : | Expanded Access |
| Expanded Access Type : | Treatment IND/Protocol |
| Official Title: | Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Multiple sclerosis
MedlinePlus related topics:
Multiple Sclerosis
Intervention Details:
- Drug: Intrathecal MSC-NP injection
Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.
10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
Criteria
Inclusion Criteria:
- Diagnosis of MS as defined by the McDonald criteria
- Diagnosis of primary progressive or secondary progressive MS
- Patients will be 18 years or older
- Significant disability shown by an Expanded Disability Status Score (EDSS, [5]) ≥4.5 that was not acquired within the last 12 months *(Patients with moderate to severe cerebellar dysfunction who have an EDSS of <6.5 who are not eligible for our Ph II Version Date: 11/21/18 Version #4 9 study will be included. This is because EDSS scores are heavily related to muscle strength and not balance or coordination and most accurately reflect paraparesis. Also there are patients with MS who have disabling upper limb coordination dysfunction but EDSS scores of better than 6.5 who are not suitable for the Phase II study but may benefit from this therapy).
- Stable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months
- Does not qualify for the inclusion/exclusion criteria of our Phase II stem cell trial. For example, patients with EDSS >6.5 or MS symptom onset and/or duration of disease >15 years
Exclusion Criteria:
- All patients who have had any prior stem cell treatments, including HSCT
- Pregnant or nursing mothers or any woman intending to become pregnant in the next three years
- Use of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure
- History of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection
- Patients who are anticipated to have difficultly accessing the intrathecal space related to scoliosis, obesity, or any other relevant factors determined by the PI.
- Patients who have not tried available therapies for their progressive MS
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822858
Contacts
| Contact: Saud A Sadiq, MD, FAAN | 212 265 8070 | atahir@tischms.org | |
| Contact: Alifiya Tahir, BDS, MPH | 212 265 8070 | atahir@tischms.org |
Locations
| United States, New York | |
| Tisch MS Research Center of New York | |
| New York, New York, United States, 10019 | |
| Contact: Alifiya Tahir, BDS, MPH 212-265-8070 atahir@tischms.org | |
| Principal Investigator: Saud A. Sadiq, MD | |
Sponsors and Collaborators
Tisch Multiple Sclerosis Research Center of New York
Investigators
| Principal Investigator: | Saud A Sadiq, MD, FAAN | Tisch MS Research Center of New York |
Additional Information:
Publications:
| Responsible Party: | Tisch Multiple Sclerosis Research Center of New York |
| ClinicalTrials.gov Identifier: | NCT03822858 History of Changes |
| Other Study ID Numbers: |
TISCHMS-MSCNP-003 |
| First Posted: | January 30, 2019 Key Record Dates |
| Last Update Posted: | September 10, 2019 |
| Last Verified: | September 2019 |
Keywords provided by Tisch Multiple Sclerosis Research Center of New York:
|
Mesenchymal Stem Cells Neural Progenitors Autologous Bone Marrow Multiple Sclerosis |
Additional relevant MeSH terms:
|
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |